Pipeline Database

UB438

Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.

Submit a Project Finished Dosage Form DB

UB438

IndicationsAmyotrophic lateral sclerosis

ClinicalCN - Pre-IND

TherapeuticsNeurology

ModalitiesProtein

Exclusive Summary

Differentiated Delivery Format: UB438 utilizes a unique Nasal Spray formulation, offering superior compliance for ALS patients (who often suffer from dysphagia) compared to oral or injectable competitors.
De-risked Mechanism of Action: Built on the same proprietary ECIWEP platform as the lead asset (UBD001) which holds FDA Orphan Drug and Breakthrough Therapy designations, reducing biological risk via a validated neuro-repair mechanism.
Manufacturing Scalability: As a "cell-free" protein therapy, it offers high batch-to-batch consistency and lower production costs compared to stem cell or exosome therapies, presenting a strong commercial barrier.

Asset Materials

UB438 Asset Materials

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here